Certara Inc. (NASDAQ:CERT) Maintains "Outperform" Rating by Leerink Partners

Core Viewpoint - Certara Inc. is a significant entity in the Medical - Biomedical and Genetics industry, focusing on software and services that expedite drug development. The company has received an "Outperform" rating from Leerink Partners, indicating a positive outlook for investors [1][5]. Financial Performance - The recent earnings report indicated a quarterly earnings per share (EPS) of $0.09, which was below the Zacks Consensus Estimate of $0.11, resulting in a negative surprise of 20.57%. This EPS also represents a decline from $0.15 in the same quarter last year [2][5]. - Certara reported quarterly revenue of $103.65 million for the period ending December 2025, slightly exceeding the Zacks Consensus Estimate by 0.41%. This revenue reflects an increase from $100.36 million reported in the same quarter of the previous year [3][5]. Stock Performance - Certara's stock is currently trading at $6.61, showing a minor increase of 0.23% or $0.015. The stock has fluctuated between a low of $6.04 and a high of $6.66 on the same day. Over the past year, the stock reached a high of $15.38 and a low of $6.04 [4]. - The company has a market capitalization of approximately $1.05 billion, with a trading volume of 2,780,555 shares [4].